Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis

Thorax

Volumn 72, Issue 2, 2017, Pages 148-153

  Kreuter, Michael ^a,b   Bonella, Francesco ^c   Maher, Toby M ^d   Costabel, Ulrich ^c   Spagnolo, Paolo ^e   Weycker, Derek ^f   Kirchgaessler, Klaus Uwe ^g   Kolb, Martin ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEMBER OF THE GERMAN CENTER FOR LUNG RESEARCH DZL   (Germany)

^c RUHRLANDKLINIK   (Germany)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PADOVA   (Italy)

^f POLICY ANALYSIS INC PAI   (United States)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIRFENIDONE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; PYRIDONE DERIVATIVE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIX MINUTE WALK TEST; ADULT; CLINICAL TRIAL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84991730431     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-208819     Document Type: Article

References (40)

1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
3. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015;192:e3-19.
4. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015;46:186-96.
5. Durheim MT, Collard HR, Roberts RS, et al. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med 2015;3:388-96.
6. American Cancer Society. Cancer facts and figures 2016. American Cancer Society, 2016.
7. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221-9.
8. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:285-92.
9. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92.
10. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
11. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
12. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE 2016;11: e0151425.
13. Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol 2015;201(Suppl 1):S1-7.
14. Briel M, Vale N, Schwartz GG, et al. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14, 000 patients. Int J Cardiol 2012;158:93-100.
15. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007;176:742-7.
16. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014;370:2201-10.
17. Fernández AB, Karas RH, Alsheikh-Ali AA, et al. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008;134:824-30.
18. Xu JF, Washko GR, Nakahira K, et al. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012;185:547-56.
19. Saad N, Camus P, Suissa S, et al. Statins and the risk of interstitial lung disease: a cohort study. Thorax 2013;68:361-4.
20. Schroll S, Lange TJ, Arzt M, et al. Effects of simvastatin on pulmonary fibrosis, pulmonary hypertension and exercise capacity in bleomycin-treated rats. Acta Physiol (Oxf ) 2013;208:191-201.
21. Nadrous HF, Ryu JH, Douglas WW, et al. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004;126:438-46.
22. Vedel-Krogh S, Nielsen SF, Nordestgaard BG. Statin use is associated with reduced mortality in patients with interstitial lung disease. PLoS ONE 2015;10:e0140571.
23. Allison PD. Survival analysis using SAS: a practical guide. 2nd edn. North Carolina: SAS Insitute Inc, 2010.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
25. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
26. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
27. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-43.
28. Chambers RC, Mercer PF. Mechanisms of alveolar epithelial injury, repair, and fibrosis. Ann Am Thorac Soc 2015;12(Suppl 1):S16-20.
29. Günther A, Korfei M, Mahavadi P, et al. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 2012;21: 152-60.
30. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-80.
31. Riessen R, Axel DI, Fenchel M, et al. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res Cardiol 1999;94:322-32.
32. Watts KL, Sampson EM, Schultz GS, et al. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005;32:290-300.
33. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-27.
34. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987-93.
35. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003;167:1271-8.
36. Ahn MH, Park BL, Lee SH, et al. A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. Respir Res 2011;12:73.
37. Hayden JM, Swartfiguer J, Szelinger S, et al. Lysophosphatidylcholine stimulation of alveolar epithelial cell interleukin-8 production and neutrophil chemotaxis is inhibited by statin treatment [abstract]. Proc Am Thorac Soc 2005;2:A72.
38. Oka H, Ishii H, Iwata A, et al. Inhibitory effects of pitavastatin on fibrogenic mediator production by human lung fibroblasts. Life Sci 2013;93:968-74.
39. Coward WR, Marei A, Yang A, et al. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006;176:5284-92.
40. Hoshino T, Okamoto M, Sakazaki Y, et al. Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 2009;41:661-70.